The role of hypoxia in increasing radioresistance in experimental tumours is well documented (Powers & Tolmach, 1963 ; see review by Moulder & Rockwell, 1987) . Its importance in human tumour treatment has been long suspected (Mottram, 1936; Thomlinson & Gray, 1955) , but the routine measurement of hypoxia in human tumours has been difficult to achieve. One approach which shows promise (Chapman, 1991) is based on the observation that 2-nitroimidazole compounds are metabolically activated and bind to hypoxic mammalian cells (Varghese et al., 1976; Varghese & Whitmore, 1980) . Generally speaking, the rate of binding increases over the same oxygen concentration range in which radiation resistance is significantly increased . A variety of techniques for detecting the binding of suitably labelled 2-nitroimidazoles to hypoxic tumour cells have been clinically tested, including autoradiography (Urtasun et al., 1986) , positron emission transaxial tomography ('8F-PETT) (Koh et al., 1992) and single-photon emission computed tomography ('25I-SPECT) (Mannan et al., 1991) . A non-invasive '9F magnetic resonance spectroscopy (MRS) approach using the fluorinated 2-nitroimidazole, CCI-103F, has been developed and tested in experimental tumours Maxwell et al., 1989; Raleigh et al., 1986 Raleigh et al., , 1991 . Technically simple, immunochemical alteratives to these techniques became feasible with the preparation of polyclonal antibodies to an antigen formed by the binding of CCI-103F to proteins under hypoxic conditions (Raleigh et al., 1987) . Initially, immunohistochemistry combined with morphometric analysis was used to provide a measure of the fraction of cells in sections of tumour tissue which bound CCI-103F (Cline et al., 1990) . However, for repetitive measurements of tumour hypoxia the immunohistochemical technique was relatively slow and labour intensive. Enzyme-linked immunosorbent assay (ELISA) and fluorescence-activated cell sorting (Hodgkiss et al., 1991) were possible alternatives. These techniques give up the spatial resolution of the immunohistochemical approach but maintain the dependence on cellular biochemistry and could provide convenient measures of hypoxia marker binding for use in multiple biopsy samples. Preliminary studies indicated the possible usefulness of the ELISA approach (Raleigh et al., 1992) . Details of the ELISA approach to measuring tumour hypoxia and its application to the measurement of hypoxia in spontaneous canine tumours are reported here.
Materials and methods
The hypoxia marker, 1-[2-hydroxy-3-(1,1,1 ,3,3,3-hexafluoroisopropoxy)propyl]-2-nitroimidazole (CCI-103F), its tritiumlabelled analogue ([3H]CCI-103F) (Raleigh et al., , 1991 and rabbit polyclonal antibodies to haemocyanin-bound CCI-103F were prepared as described previously (Raleigh et al., 1987) . Bovine serum albumin (BSA, fatty acid and globulin free), goat anti-rabbit IgG conjugated to alkaline phosphatase, phenylmethylsulphonyl fluoride (PMSF), 5,5'-dithiobis(2-nitrobenzoic acid) (Ellman's reagent) The pellet formed upon centrifugation of the proteinase K digest of 0.5 ml of [3H]CCI-103F-labelled liver homogenate (see below) was dissolved in a small volume of chloroform for TLC analysis. The supernatant (1.0 ml) over the proteinase K pellet was extracted with 2 x 3 ml of a 2: 1 chloroform-methanol mixture, the extract back-extracted with water and the organic phase taken to dryness and analysed by TLC. Two TLC solvent systems were used: (a) chloroform-methanol-water (65:25:4) and (b) chloroformmethanol (95:7). Samples of the extracts were spotted at the origin of TLC plates, which were then developed in a solvent-saturated chamber. The plates were air-dried and sprayed with 50% aqueous sulphuric acid. Upon heating, the plates developed charred spots at locations containing lipids.
The plates were cut into 0.5 cm strips and the tritium content of the strips measured by adding them to 1O ml of ScintiVerse II (Fisher) in scintillation vials and counting the vials by means of a Beckman Model LS 5000 TA scintillation counter.
Preparation of tissue-bound CCI-103F calibration standard The calibration method for the ELISA was based on parallel ELISA and scintillation counting measurements of the amount of tritium-labelled CCI-103F covalently bound in vivo to canine tumour or liver tissues. A preliminary account of the in vivo labelling procedure has been reported (Raleigh et al., 1992) . Briefly, a 0.9% saline solution containing tritiated CCI-103F (specific activity 9.87 iLCi mg-') was injected as an infusion of O min duration into the cephalic vein of a tumour-bearing, 25.5 kg dog which was scheduled for euthanasia. The whole-body concentration of CCI-103F was approximately 118 pmol kg-' of body weight. Liver and tumour tissues were collected 24 h later at autopsy and stored at -20°C.
Preparation of a BSA -hapten conjugates Tritium-labelled and unlabelled CCI-103F was reductively bound to BSA by means of a published procedure for the radiation chemical binding of 2-nitroimidazoles to thiol-rich proteins (Raleigh & Koch, 1990) . The tritiated CCI-103F-BSA conjugate was used as a calibration standard for the ELISA, while the unlabelled conjugate was used as a solid phase, coating antigen in the competitive ELISA described below. For the purpoose of conjugate preparation, CCI-103F was reductively activated by electrons produced by water radiolysis. Briefly, bovine serum albumin at 1 mg ml-' was dissolved in 25 ml of 50 mM phosphate buffer (pH 7.5) containing 100 mM sodium formate. The solution was divided into 5 ml aliquots and each aliquot deoxygenated by means of nitrogen gas flowing over the rapidly stirred solutions for 60 min in five septum-sealed, 30 ml serum bottles.
The deoxygenated solutions were irradiated in a 13'CS gamma source to 800 Gy in order to reduce some of the 34 disulphide moieties in BSA to thiol groups, which are known to bind avidly to reductively activated 2-nitroimidazoles (Raleigh & Koch, 1990) . Typically, a protein thiol concentration of 200 JAM as measured by Ellman's reagent (Ellman, 1959) (Raleigh & Koch, 1990) . It was assumed that a similar degree of 'cold' CCI-103F binding to BSA occurred. The combined solutions were then dialysed and concentrated to 1.0 ml by means of diafiltration with an Amicon Centriprep concentrator. The concentrated solutions were stored at -20°C.
ELISA of [3H]CCI-103F-labelled canine tissues
Weighed samples of canine liver or tumour tissue (10-100 mg) containing covalently bound [3H]CCI-103F were minced and suspended in 10 volumes of a phosphatebuffered saline-0.05% Tween (PBS-Tween) solution in a 5 ml round-bottomed glass tube. The suspension was thoroughly homogenised by means of an Omni Mixer fitted with a Minimicro generator. At this point, an aliquot of the homogenate was taken for protein determination by the BCA reagent. For the ELISA measurement of tissue-bound CCI-103F, the homogenates were diluted 1:1 with PBS-Tween containing I mg ml-' proteinase K (20 units mg-') and the mixture incubated overnight at 37°C in a shaking water bath. The enzyme inhibitor, phenylmethylsulphonyl fluoride (PMSF), was added at a final concentration of 200 JAM and the reaction mixture incubated for 5 min at room temperature. For ELISA on tissues containing low concentrations of bound CCI-103F, it was found necessary to add a second aliquot of PMSF to a final concentration of 400 JAM followed by heating for 10 min at 95°C in a hot water bath in order to completely inactivate the proteinase K. This procedure was adopted for all samples. The digested sample was centrifuged for 10 min at 10,000 r.p.m. in an Eppendorf model 5415 microfuge in order to pellet particulate material. For the ELISA, the calibration standards, whether tissuederived or synthetic BSA-CCI-103F conjugates, were hydrolysed with proteinase K and otherwise treated as the tumour tissue samples. The material in the pellet formed by centrifugation of the proteinase K digest tended to be fluffy and could be dispersed by vortexing. However, as discussed below, aliquots of the supernatant only were carefully drawn off and used for the ELISA.
The supernatants from the homogenised, digested and centrifuged samples were serially diluted in polyvinyl microassay plate wells for preincubation with anti-CCI-103F rabbit antiserum. To each of the 100ly samples in the wells was added 25 1tl of anti-CCI-103F rabbit antiserum solution diluted 1:200 in PBS-Tween. The plate was covered tightly with Parafilm and incubated for 2 h at 37°C. The contents of each well of the polyvinyl microassay plate were then transferred to the wells of polystyrene ELISA plates, the surfaces of which had been coated with the solid phase CCI-103F antigen bound to BSA. Uncoated surfaces had been blocked against non-specific binding of the rabbit antiserum by a treatment with 1% goat serum in PBS-Tween pH 7.4 for 2 h at 37°C. In addition to standards, two test samples were arranged in quadruplicate in each plate.
The competition between solid phase and soluble CCI-103F antigens for the anti-CCI-103F rabbit antiserum was allowed to proceed for 2 h at 37°C in the ELISA plates. The wells were then washed four times with PBS-Tween and 100 fsl of a working concentration of a 1:1000 alkaline phosphatase-conjugated, goat anti-rabbit IgG was added to each well. Following a 2 h incubation at 37°C, the plates were against washed four times with PBS-Tween and then three times with 10% diethanolamine in water, pH 9.8. To each well was added 50Jl of a 1 mg ml' solution of the alkaline phosphatase substrate, 4-nitrophenyl phosphate, in 10% diethanolamine. The development of colour at 405 nm was followed by means of a Molecular Devices Vmax kinetic plate reader. The data were analysed and plotted with the aid of A Soft II Version 3.3. ELISAnalysis software (Biometallics) in conjunction with a Macintosh Ilsi computer (Apple Computer) and a Cricket Graph software package (Computer Associates).
Selection and irradiation of canine tumours Privately owned dogs with spontaneous tumours were selected from the Oncology Service of the North Carolina State University College of Veterinary Medicine. The dogs remained the property of the owners. The study reported here was approved by the Institutional Animal Care and Use Committee of North Carolina State University. Tumour types were confirmed by histopathology. A list of tumour types used in the development stages of the ELISA technique is given in Table I .
In one illustrative case of the application of ELISA to a tumour undergoing radiation treatment, a scapular fibrosarcoma was irradiated with cobalt-60 photons given in daily (Monday to Friday) 3.0Gy fractions. The dog was under general anaesthesia for biopsy and irradiation. Anaesthesia was induced and maintained with isoflurane. The fractional inspired oxygen value during irradiation was 100%. The dog (Table I) , tumours were excised and frozen for subsequent ELISA analysis. In a second type of experiment involving unlabelled CCI-103F only (Table II) , CCI-103F was injected and 24 h later -just before the first dose of fractionated 'Co gamma-irradiation -two 50 mg biopsy samples were taken from different regions of the canine tumour by means of a 14 gauge Trucut needle. All biopsies were carried out under aseptic conditions. Additional paired biopsies were taken at 72 h after the injection of CCI-103F in order that the kinetics of the loss of tissuebound CCI-103F might be estimated. The second injection of CCI-103F occurred just before the sixth dose of 3 Gy. A weekend intervened in the treatment so that the biopsies were taken on day 8, at which time the dog had received 15 Gy of radiation. The biopsy procedure for the first injection was repeated for the second injection. (Figure 2 ). that a 2:1 chloroform-methanol solvent extracted 30% of the radioactivity from the liver homogenate prior to proteinase K digestion, which was close to the amount of radioactivity found in pellets after centrifugation of the proteinase K digest of the liver tissue homogenate (see above). Chloroform-methanol extracts of tumour homogenates, liver homogenates and chloroform extracts of the pellets formed in the proteinase K digest of the tissue homogenates behaved in the same way upon TLC analysis (data not shown). In these cases, radioactivity was concentrated on the TLC plate in a few major bands which contained materials more polar than cholesterol but less polar than phosphatidylcholine. The mixed, 2:1 chloroform-methanol solvent extracted very little radioactivity (c. 8%) from the supernatant of the proteinase K digests. Owing to the small amount of radioactivity, a TLC analysis of this extract was not possible. Further attempts to identify the CCI-103F-conjugated lipids has not been made. It was noted in the TLC analyses that essentially no radioactivity appeared where unchanged CCI-103F migrated.
The addition of 1.2% Triton X-100 to the tissue homogenates with proteinase K was effective in solubilising c. 98% of the radioactivity derived from tissue-bound [3H]CCI-103F, but this procedure significantly lowered the sensitivity of the ELISA. Furthermore, the amount of CCI-103F bound to the particulate matter in the proteinase K digest of the tumour tissue as distinct from that of the liver tissue was small. Therefore, for the purposes of the present study, the ELISA was restricted to an analysis of the supernatant of the proteinase K digest of the homogenates.
ELISA measurement of CCI-103F binding to canine tumours In a preliminary study, multiple small tissue samples were taken from a variety of excised tumours and analysed by ELISA in an attempt to address the question of how representative biopsy samples might be. The results are summarised in Table I . In those cases where three or more samples (n = 3 to n = 10) from a single tumour were analysed, the standard deviation of the mean ranged from 9% to 50%. Figure 3 Immunostaining of a tissue section prepared from a Trucut biopsy taken from a canine scapular fibrosarcoma 24 h after the first injection of CCI-103F. ELISA data for this tumour are presented in Table II . Magnification x 100. (Smith, 1984) with only small amounts to lipids (c. 2%) (Miller et al., 1982) and nucleic acids (c. 4%) (Smith, 1984) . Protein thiols are particularly efficient at binding reductively activated 2-nitroimidazoles, including misonidazole and CCI-103F (Raleigh & Koch, 1990 (Cobb et al., 1992; Van Os-Corby et al., 1987) and [3H]CCI-103F-labelled liver tissue was seen as a useful source of material for calibrating the ELISA. The antisera to CCI-103F were known to respond strongly to the hexafluorinated side chain of CCI-103F (Raleigh et al., 1987) (Urtasun et al.,1986) (Chapman, 1991) . Smaller ranges of binding intensities of 2-3 were observed for transplanted murine tumours possessing the similar hypoxic fractions (Franko, 1986; Hirst et al., 1985) .
While binding intensity in experimental tumours of a single type can be directly related to radiobiological hypoxic fraction or radiation response (Hirst et al., 1985; Li et al., 1991) . The value of the immunochemical approach in this context is that a single set of reagents provides for a rapid and inexpensive means of following changes in hypoxia marker binding (ELISA), which can be related to the fraction of cells binding the marker (immunohistochemical analysis) in the same biopsy samples (Cline et al., 1990) . The high sensitivity of the ELISA should allow for the analysis of very low residual levels of hypoxia marker binding in a shrinking tumour. Of course, the untested assumption in these studies is that the inherent hypoxia marker-binding capacity of the tumour cells remains unchanged during treatment.
In summary, knowledge of the exact chemical nature of the hypoxia marker antigens does not appear to be critical for the purposes of ELISA measurement of the relative intensities of hypoxia marker binding in tumour tissue. While the ELISA described here was calibrated against both synthetic and tissue-derived antigens, the synthetic antigen derived from BSA is easier to generate and ultimately could be prepared in a non-radioactive form. The response of the synthetic antigen in the ELISA appears to be different from that of the tissue-derived antigen and, in those cases where an estimate of the absolute amount of CCI-103F bound to tissue is desired, the synthetic standard appears to underestimate the amount of CCI-103F bound in vivo. A correction factor can be applied to account for the difference which, in our particular case, is 2.2. The ELISA has been successfully applied to following changes in hypoxia marker binding during radiation therapy without the need for radioactive reagents being injected into the canine patients. The ELISA has the advantages in a clinical setting of being very sensitive, dependent on routine tumour biopsy and ELISA procedures and well adapted to the rapid analysis of multiple samples generated by multiple biopsy samples during a course of radiation treatment. Ultimately, a combination of immunohistochemical analysis and ELISA might prove to be an effective way of estimating tumour hypoxia and its changes during therapy.
